Abstract Aims Electrochemotherapy (ECT) combines the use of low-dose chemotherapy with reversible electroporation to increase intracellular uptake of chemotherapeutic agents and improve tumoral cytotoxicity. Although a well-established treatment modality in primary skin and cutaneous metastases, the effects of ECT in the treatment of advanced oesophagogastric cancer are unknown. Development of the endoVE/ePORE system now allows endoscopic delivery of ECT. We aim to recruit thirty patients to the VECTOR trial to assess the efficacy of endoscopic ECT in the local treatment of inoperable oesophagogastric cancer. Methods The study began recruitment in March 2020. Patients undergo a single treatment of endoscopic ECT alongside a dose of intravenous Bleomycin. Validated dysphagia and QoL scores (Ogilvie, EORTC QLQ-C30/ OES18) are used to assess symptomatic response to treatment. Local tumour response is assessed with interval gastroscopy and cross-sectional imaging. Results Six males and one female with a mean age of 71 years (41–88) have received endoscopic ECT.Four patients had received oncological therapy prior to enrolment. The mean procedural time was 22 minutes.All patients were discharged within 24 hours of treatment.Over 50% of patients reported significant improvements in their dysphagia score at 6-week follow-up with concomitant improvement in their QoL metrics. Conclusions Early experience of endoscopic ECT is safe, well tolerated and can be performed in the endoscopy suite with sedation and analgesia. Improvements in patients’ symptomatology are promising and may indicate this as an alternative to stenting.We are yet to demonstrate favourable tumour response on follow up imaging and endoscopy.Careful patient selection is key to negate post procedural complications.